PDE3 cyclic nucleotide phosphodiesterases and the compartmentation of cyclic nucleotide-mediated signalling in cardiac myocytes.
PDE3 cyclic nucleotide phosphodiesterase inhibitors raise cAMP and cGMP content in cardiac and vascular myocytes. Their administration to patients with dilated cardiomyopathy leads to improvements in hemodynamic parameters in the short term but reduces survival with chronic administration. The reasons for this 'biphasic' response have not been elucidated, but it is likely that beneficial and harmful effects of PDE3 inhibition reflect the phosphorylation of different substrates of cAMP- and cGMP-dependent protein kinases (PK-A and PK-G). It is now apparent that cardiac and vascular myocytes contain several isoforms of PDE3 that differ in their intracellular distribution and thus regulate cAMP and cGMP levels in different subcellular compartments. These isoforms also differ in their regulation by extracellular signals that may be important in the pathophysiology of dilated cardiomyopathy. An intriguing possibility is that the beneficial and harmful effects of PDE3 inhibition may be attributable to the inhibition of different isoforms of these enzymes.
Movsesian
Matthew A
MA
Cardiology Section, VA Salt Lake City Health Care System, 500 Foothill Drive, Salt Lake City, UT 84148, USA. matthew.movsesian@med.va.gov
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000235:genetics / Q000502:physiology*; D000818:Animals; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism; D008967:Molecular Biology; D032383:Myocytes, Cardiac / Q000502:physiology*; D009712:Nucleotides, Cyclic / Q000502:physiology*; D015398:Signal Transduction / Q000502:physiology
D007527:Isoenzymes; D009712:Nucleotides, Cyclic; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3